IRIS
CIVES, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.303
AS - Asia 2.130
EU - Europa 1.400
SA - Sud America 662
AF - Africa 100
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.603
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.216
SG - Singapore 843
BR - Brasile 519
CN - Cina 481
IT - Italia 295
HK - Hong Kong 262
SE - Svezia 221
RU - Federazione Russa 197
VN - Vietnam 194
FI - Finlandia 140
FR - Francia 128
DE - Germania 121
GB - Regno Unito 107
IN - India 73
AR - Argentina 55
ID - Indonesia 49
BD - Bangladesh 41
CA - Canada 41
IQ - Iraq 38
ZA - Sudafrica 29
MX - Messico 27
JP - Giappone 26
TR - Turchia 26
CI - Costa d'Avorio 25
NL - Olanda 25
AT - Austria 23
CO - Colombia 22
PL - Polonia 22
UA - Ucraina 22
BE - Belgio 21
PK - Pakistan 18
ES - Italia 14
VE - Venezuela 14
EC - Ecuador 13
IE - Irlanda 13
LT - Lituania 13
MA - Marocco 12
PH - Filippine 12
PY - Paraguay 12
SA - Arabia Saudita 12
CL - Cile 10
BO - Bolivia 7
KE - Kenya 7
UZ - Uzbekistan 7
JO - Giordania 6
MY - Malesia 6
RS - Serbia 6
TN - Tunisia 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
CR - Costa Rica 5
EG - Egitto 5
ET - Etiopia 5
MK - Macedonia 5
OM - Oman 5
HU - Ungheria 4
PE - Perù 4
TH - Thailandia 4
AU - Australia 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
NP - Nepal 3
RO - Romania 3
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
LB - Libano 2
MN - Mongolia 2
MT - Malta 2
NZ - Nuova Zelanda 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
IR - Iran 1
IS - Islanda 1
JE - Jersey 1
KG - Kirghizistan 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MM - Myanmar 1
NG - Nigeria 1
NI - Nicaragua 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 8.596
Salva come PNG Salva come JPEG
Città #
Ashburn 558
Fairfield 502
Singapore 457
Woodbridge 389
Hong Kong 259
Houston 231
Seattle 219
Chandler 210
Cambridge 203
Beijing 195
San Jose 193
Nyköping 186
Wilmington 186
Ann Arbor 123
Helsinki 109
Los Angeles 80
Lauterbourg 78
Dallas 64
Lawrence 64
Ho Chi Minh City 63
Jacksonville 60
Roxbury 58
New York 53
Council Bluffs 47
Bari 46
São Paulo 44
Jakarta 41
Nanjing 39
Des Moines 36
Chicago 32
London 31
Buffalo 30
Santa Clara 29
Inglewood 28
Munich 28
Abidjan 24
Hanoi 24
Dong Ket 23
Falkenstein 23
Paris 23
Rome 22
Tokyo 22
Redwood City 21
Brooklyn 20
Johannesburg 20
Brussels 19
San Diego 19
Nuremberg 18
Warsaw 18
Brasília 17
Belo Horizonte 15
Chennai 15
Moscow 15
Orem 15
Princeton 15
Curitiba 14
Turku 14
Dublin 13
Frankfurt am Main 13
Buenos Aires 12
Montreal 12
Rio de Janeiro 12
Baghdad 11
Düsseldorf 11
Boardman 10
Mexico City 10
Shenyang 10
Stockholm 10
Toronto 10
Vienna 10
Dearborn 9
Elk Grove Village 9
Haiphong 9
Nanchang 9
Porto Alegre 9
Can Tho 8
Changsha 8
Denver 8
Medellín 8
Milan 8
Pune 8
Amsterdam 7
Ankara 7
Atlanta 7
Dhaka 7
Guangzhou 7
Ninh Bình 7
Phoenix 7
San Francisco 7
Vibo Valentia 7
Bologna 6
Calgary 6
Da Nang 6
Hebei 6
Istanbul 6
Jiaxing 6
Montevideo 6
Naples 6
Riyadh 6
Salt Lake City 6
Totale 5.747
Salva come PNG Salva come JPEG
Nome #
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors 251
Gastroenteropancreatic Neuroendocrine Tumors 184
Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity 177
Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro 170
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression 167
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 167
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition 164
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe 161
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. 161
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study 160
New insights into the molecular pathogenesis of langerhans cell histiocytosis 156
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications 156
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. 154
Erdheim-Chester disease: A systematic review. 153
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations 152
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition 152
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. 148
NETs: Organ-related epigenetic derangements and potential clinical applications 145
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 139
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. 136
Analysis of the immune landscape of small bowel neuroendocrine tumors 134
An update on Merkel cell carcinoma 129
Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease 129
Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors 125
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors 121
Lenalidomide in multiple myeloma: current experimental and clinical data 120
The management of refractory carcinoid syndrome: challenges and opportunities ahead 118
SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand 117
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors 116
The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors 114
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer 110
A phase II study of axitinib in advanced neuroendocrine tumors 110
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors 108
Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice 106
Local treatment for focal progression in metastatic neuroendocrine tumors 105
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials 105
1101MO Development of CAR T-cells for future treatment of NETs 104
Effect of vitaxin on hyperactive osteoclastogenesis in multiple myeloma: a preclinical study 103
Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems 101
Radionuclide Therapy for Neuroendocrine Tumors 100
Cell fusion in myeloma marrow microenvironment: role in tumor progression 98
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 97
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 97
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 97
Local treatment for focal progression in metastatic neuroendocrine tumors 96
Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. 95
In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients 95
An update on gastroenteropancreatic neuroendocrine tumors 94
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 94
Novel Lenalidomide-based combinations for treatment of multiple myeloma 91
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms 91
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors 89
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 88
Non-Melanoma Skin Cancers: Biological and Clinical Features 87
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 86
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 85
Therapy for locoregional disease: pancreas 85
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 84
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 84
Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results 83
Management of NETs in the Precision Medicine Era 81
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment 81
Lanreotide dopo octreotide LAR nel pNET in progressione: descrizione di un caso 79
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 76
Sensitivity and Specificity of the NETest: A Validation Study 76
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%? 74
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML 71
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 66
Neuroendocrine tumors 65
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours 65
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 65
EPB41L5 is Associated with the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors 63
An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs 61
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms 59
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 56
A challenge in emergency department: a case report of oxaliplatin-induced Kounis syndrome 50
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 47
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM) 44
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients 41
Is NETTER-2 a practice-changing trial? 40
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial 39
The future of cellular therapy for the treatment of renal cell carcinoma 37
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 37
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence 33
In Defense of Neuroendocrine Tumor Trials 31
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 31
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis 27
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? 24
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries 24
The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion 22
White paper on best practices for translational research in neuroendocrine neoplasms 22
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study 22
SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia 20
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors 12
Totale 8.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.416
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021192 0 0 0 0 0 0 0 0 0 95 43 54
2021/2022444 42 19 3 10 17 50 14 18 38 37 71 125
2022/2023636 91 111 47 31 37 92 19 87 82 2 17 20
2023/2024313 19 55 14 38 35 63 18 11 6 13 4 37
2024/20251.610 49 27 128 83 57 129 162 129 96 164 207 379
2025/20263.420 557 200 255 472 409 210 380 143 447 347 0 0
Totale 8.985